Article
Genetic characterization of ABT-199 sensitivity in human AML.
Leukemia - 1 Jan 2020
Bisaillon Richard, Moison Céline, Thiollier Clarisse, Krosl Jana, Bordeleau Marie-Eve, Lehnertz Bernhard, Lavallée Vincent-Philippe, MacRae Tara, Mayotte Nadine, Labelle Caroline, Boucher Geneviève, Spinella Jean-François, Boivin Isabel, D'Angelo Giovanni, Lavallée Sylvie, Marinier Anne, Lemieux Sébastien, Hébert Josée, Sauvageau Guy
Abstract excerpt
Acute myeloid leukemias (AML) with mutations in the NPM1 gene (NPM1c+) represent a large AML subgroup with varying response to conventional treatment, highlighting the need to develop targeted therapeutic strategies for this disease. We screened a library of clinical drugs on a cohort of primary human AML specimens and identified the BCL2 inhibitor ABT-199 as a selective agent against NPM1c+ AML. Mutational...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.